Biovie Inc Stock Price, News & Analysis

BioVie (NASDAQ: BIVI), a clinical-stage company focused on liver disease and neurological disorder therapies, has completed a $12 million public offering. The offering consisted of 6,000,000 units priced at $2.00 per unit, with each unit containing one common stock share and one warrant.

The warrants (NASDAQ: BIVIW) are immediately exercisable at $2.50 per share with a five-year expiration. The underwriter exercised a partial over-allotment option for an additional 667,300 warrants. The company plans to use the proceeds for working capital and general corporate purposes.

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing therapies for liver disease and neurological disorders, has announced the pricing of a $12 million public offering. The offering consists of 6,000,000 units priced at $2.00 per unit, with each unit comprising one share of common stock and one warrant.

The warrants (BIVIW) will be tradable on Nasdaq starting August 8, 2025, with a $2.50 exercise price and 5-year expiration. ThinkEquity serves as the sole book-running manager, with a 45-day over-allotment option for additional securities. The offering is expected to close on August 11, 2025, with proceeds intended for working capital and general corporate purposes.

BioVie (NASDAQ: BIVI) presented promising data from their Phase 3 NM101 study of Bezisterim at the 2nd World Conference on Aging and Gerontology. The study revealed that Alzheimer's Disease patients treated with Bezisterim experienced significant age deceleration compared to placebo across multiple biological clocks.

Key findings showed age deceleration advantages including -3.16 years for SkinBloodClockAge (p=0.036), -4.12 years for PhenoAge (p=0.048), and -3.77 years for InflammAge (p=0.050). The treatment demonstrated improvements in metabolic and inflammatory biomarkers, including reductions of 8.5 mg/dL in fasting glucose and 15 mg/dL in cholesterol.

Bezisterim, a stabilized version of Beta AET, showed potential in modulating gene expression related to inflammation, aging, and Alzheimer's Disease pathophysiology, while maintaining favorable safety profiles.

BioVie (NASDAQ: BIVI) presented promising data on bezisterim at the 7th World Aging and Rejuvenation Conference, highlighting its potential to slow biological aging and neurodegeneration. The Phase 3 NM101 study analysis revealed that bezisterim-treated Alzheimer's patients showed significant biological age reduction compared to placebo across multiple epigenetic clocks, with differences ranging from -1.38 to -4.24 years.

The study demonstrated bezisterim's ability to modulate inflammation and gene activation, with treated patients showing significant improvements in key biomarkers including -8.5 mg/dL in fasting glucose, -15 mg/dL in cholesterol, and -90.5 pg/mL in MCP. Bezisterim, a stabilized version of Beta AET, uniquely offers oral availability and blood-brain barrier penetration while maintaining favorable safety profiles in Alzheimer's and Parkinson's Disease trials.

BioVie (NASDAQ: BIVI) announced the presentation of its SUNRISE-PD Phase 2 clinical trial design at the Advanced Therapeutics in Movement & Related Disorders® Congress. The trial evaluates bezisterim (NE3107) in early-stage Parkinson's Disease patients through a hybrid, decentralized approach.

The innovative trial design allows participants aged 41-80, diagnosed within the last four years, to complete visits either at home or in clinic. The study features in-home nurse visits, neurologist oversight via video conferencing, and remote assessment of motor symptoms. BioVie has partnered with organizations including The Michael J. Fox Foundation to support enrollment.

Bezisterim is an oral, anti-inflammatory, insulin-sensitizing compound that has demonstrated improvements in both motor and non-motor symptoms in previous trials, targeting key biological processes in PD progression.

BioVie (NASDAQ: BIVI) announced it will present a poster highlighting its Phase 2 SUNRISE-PD clinical trial at the Advanced Therapeutics in Movement & Related Disorders® Congress from June 27-30, 2025. The presentation will focus on the trial's decentralized design and patient experience in evaluating bezisterim (NE3107) for early Parkinson's disease treatment.

The Phase 2b SUNRISE-PD trial is a multicenter, randomized, double-blind, placebo-controlled study with a hybrid decentralized design lasting 20 weeks. Patients can participate either from home or at clinical sites, with home visits conducted by study nurses and remote neurologist supervision. The trial includes a modified MDS-UPDRS Part III examination, with successful participants potentially eligible for a longer-term, open-label safety study.

BioVie (NASDAQ: BIVI) has initiated patient enrollment in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim (NE3107) for treating neurological symptoms of long COVID. The trial, funded by the U.S. Department of Defense, is a randomized, placebo-controlled study focusing on patients with cognitive impairment and fatigue. Topline data is expected in the first half of 2026.

Long COVID affects approximately 20 million adults in the US, with 10-30% of COVID-19 patients experiencing persistent symptoms. The study aims to address the lack of approved treatment options for long COVID patients suffering from debilitating fatigue and brain fog. Bezisterim targets key neuroinflammation mechanisms and has shown potential in reducing chronic symptoms in Alzheimer's and Parkinson's disease trials.

BioVie (NASDAQ: BIVI) announced a virtual Key Opinion Leader (KOL) event scheduled for May 28, 2025, focusing on their Phase 2 trial of bezisterim (NE3107) for Parkinson's disease treatment. The event will feature experts Dr. Suzanne de la Monte from Brown University and Dr. Mark Stacy from Medical University of South Carolina.

The discussion will center on the SUNRISE-PD trial, which is currently enrolling newly diagnosed Parkinson's patients. Bezisterim is an oral small molecule designed to reverse insulin resistance and selectively inhibit inflammation-driven processes. The study aims to evaluate the drug's impact on clinical signs and biomarkers potentially related to disease modification.

BioVie (NASDAQ: BIVI) has announced the formation of a seven-member Corporate Advisory Board comprising distinguished leaders from various sectors. The board includes notable figures such as Neuralink co-founder Dr. Tim Gardner, Cedars-Sinai Memory & Aging Program Director Dr. Zaldy Tan, and former executives from Mastercard and Apple. The advisory board's primary mission is to support BioVie's clinical development efforts, inform business strategy, and enhance stakeholder engagement in developing bezisterim (NE3107), their investigational drug candidate. The drug targets neuroinflammation in conditions like Alzheimer's disease, Parkinson's disease, and long COVID. Each board member brings personal conviction and expertise in areas including biotechnology, neuroscience, venture capital, M&A, business, and communications.